The prevalence of non-communicable diseases (NCD) in Indonesia is currently increasing. Data from WHO states that 71% of the causes of death worldwide are NCD. Control of risk factors and early detection of non-communicable diseases (NCD) are the keys to reducing the number of cases and mortality of NCD. Posbindu is a preventive, promotive effort that involves community participation. The ability of cadres and community awareness are not the same in every area. In this regard, our community service activities aim to optimize cadres in controlling NCD through the establishment and implementation of Posbindu. This program consists of 5 actions: Training of cadres about Posbindu, Counseling, and education to cadres and the community about non-communicable diseases, especially hypertension and diabetes mellitus, Procurement and training on the use of medical devices for Posbindu, Creation of information and communication media for health education to the public, and Establishment of Posbindu and its implementation. The results of this program are increasing the understanding of cadres about Posbindu, increasing the knowledge of cadres and the community about NCD, and the formation of Posbindu, which has been implemented in the community. Active participation of the cadres and the community is expected to ensure the continuity of this activity.

Background: Solute Carrier Family 22 Member 1 (SLC22A1, also known as OCT1) protein has a vital role in the metabolism of metformin, a first-line anti-diabetes medication. Genetic polymorphism in SLC22A1 influences individual response to metformin. Objective: This review aims to compile the current knowledge about the effects of SLC22A1 genetic polymorphism on metformin pharmacokinetics and HbA1c levels. Methods: We followed the PRISMA 2020 standards to conduct a systematic review. We searched the publications for all appropriate evidence on the effects of SLC22A1 genetic polymorphism on metformin pharmacokinetics and HbA1c from January 2002 to December 2022. Results: Initial database searches identified 7,171 relevant studies. We reviewed 155 titles and abstracts after deleting duplicates. After applying inclusion and exclusion criteria, 23 studies remained. Conclusion: Three studies found that rs12208357, rs34059508, and G465R had a considerable impact (p < 0.05) on metformin pharmacokinetics, resulting in increased metformin plasma (Cmax), a higher active amount of drug in the blood (AUC), and lower volume of distribution (Vd) (p<0.05). SLC22A1 polymorphisms with effects on HbA1c include rs628031 (four of seven studies), rs622342 (four of six studies), rs594709 (one study), rs2297374, and rs1867351 (one of two studies), rs34130495 (one study), and rs11212617 (one study) (p < 0.05).